Albany Molecular Research Inc. (AMRI), a global contract research and manufacturing organization, has entered into an agreement with the pharmaceutical group Ferrer and Accord Healthcare, to jointly develop and manufacture an undisclosed complex parenteral drug product for registration and subsequent commercialization in the United States with the option to partner on additional drug products.

Under terms of the agreement, AMRI will work with Ferrer to develop and initially provide cGMP manufacturing and analytical support for the registration of the new product. Accord Healthcare will be responsible for advancing the product candidate through regulatory submission and commercialization.

William S. Marth, president and chief executive officer said, "As one of the fastest growing generic companies in the United States, AMRI is very impressed with Accord's performance and excited to be able to extend our deep scientific and product development expertise to help the company advance this product towards the market. Strategic partnerships, such as this agreement with Accord Healthcare, are just one example of how we can help biopharmaceutical companies enhance the value of their innovation and accelerate development and manufacturing, and at the same time we gain access to the benefits of the end market sales of the developed product when they become commercially available."

Gerald Price, president of Accord Healthcare US and Canada, said, "AMRI brings unique capabilities and experience to drug development and manufacturing. We look forward to working with AMRI and Ferrer to leverage the companies' complementary expertise and abilities to address the unique challenges involved in complex drug product development and manufacturing."

Ernest Domenech, coo of Ferrer HealthTech, said, "This agreement with Accord and AMRI provides an excellent opportunity to enter the US market with this product. We are convinced that Ferrer's expertise in the manufacturing of high quality generic drugs combined with the expertise of AMRI and Accord Healthcare will ensure the success of this project in the United States."

AMRI is a global contract research and manufacturing organization that has been working with the life sciences industry to improve patient outcomes and the quality of life for more than two decades. With locations in North America, Europe and Asia, our key business segments include Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP), and Fine Chemicals.

As part of the Intas Group, Accord Healthcare is a young and dynamic pharmaceutical company, involved in the development, manufacturing and distribution of pharmaceutical products to over 70 markets around the world.

Founded in 1959, Ferrer is a privately-held Spanish pharmaceutical company, with full vertical integration from R&D to distribution. It is present in more than 95 countries, with 24 international affiliates.